L 365 260

Manufactured by Bio-Techne

Sourced in United Kingdom

L-365,260 is a laboratory equipment product offered by Bio-Techne. It is a selective agonist of the glucagon-like peptide-1 (GLP-1) receptor.

Automatically generated - may contain errors

Lab products found in correlation

Clozapine n oxide, by Bio-Techne (1 mentions) Furosemide, by Merck Group (1 mentions) Mk 801, by Merck Group (1 mentions) Cck 8, by Bio-Techne (1 mentions) Nor bni, by Bio-Techne (1 mentions) Damgo, by Bio-Techne (1 mentions) Proglumide, by Bio-Techne (1 mentions) L364 718, by Bio-Techne (1 mentions)

4 protocols using l 365 260

Pharmacological Modulation of CCK Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Furosemide (F4381, Sigma-Aldrich), CCK-8s (4100-V, Peptide Institute), L-365,260 (2767, Tocris), A-71623 (2411, Tocris), clozapine N-oxide (CNO) (4936, Tocris), and FluoSphere-conjugated Alexa555 (A20501MP, Thermo Fisher Scientific) were used.

Matsuda T., Hiyama T.Y., Kobayashi K., Kobayashi K, & Noda M. (2020). Distinct CCK-positive SFO neurons are involved in persistent or transient suppression of water intake. Nature Communications, 11, 5692.

+ Open protocol

+ Expand

Chemical Agents for Neuroscience Research

Check if the same lab product or an alternative is used in the 5 most similar protocols

Most chemicals such as NBQX and MK801 were achieved from Sigma-Aldrich. Morphine hydrochloride was achieved from Shenyang Pharmaceutical Co. Ltd. under surveillance of Chinese Food and Drug Administration; sufentanil citrate was achieved from Renfu Pharmaceutical Co. Ltd. under surveillance of Chinese Food and Drug Administration; naloxone hydrochloride was achieved from Chongqing Lummy Pharmaceutical Co. Ltd.; CTOP was achieved from Abcam; naltrindole, nor-BNI, CCK8s, L365260, MK329, DAMGO, and CNO were achieved from Tocris. All drugs were first dissolved to a maximum concentration according to the manufacturer’s instructions, and the final solutions were prepared immediately before experiments.

Hou Y., Zou G., Wang X., Guo H., Ma X., Cheng X., Xie Z., Zuo X., Xia J., Mao H., Yuan M., Chen Q., Cao P., Yang Y., Zhang L, & Xiong W. (2023). Coordinated activity of a central pathway drives associative opioid analgesic tolerance. Science Advances, 9(6), eabo5627.

+ Open protocol

+ Expand

Chemically-Induced Long-Term Potentiation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Following the baseline recording, L-365,260 (10 µg/mL, 0.5 µL, and 0.1 µL/min, Tocris Bioscience) or ACSF was infused into the AC. This was then followed by five trials of HFS laser EC-to-AC + Pre/Post Pairing as described above. After that, we transitioned into the post-pairing recording phase.

Sun W., Wu H., Peng Y., Zheng X., Li J., Zeng D., Tang P., Zhao M., Feng H., Li H., Liang Y., Su J., Chen X., Hökfelt T, & He J. (2024). Heterosynaptic plasticity of the visuo-auditory projection requires cholecystokinin released from entorhinal cortex afferents. eLife, 13, e83356.

+ Open protocol

+ Expand

Cholecystokinin-10 Receptor Antagonists

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cholecystokinin-10 (CCK, cerulein) was purchased from Sigma-Aldrich, Inc. (St. Louis, MO, USA; Cat #17650-98-5). The following CCK receptor antagonists were purchased from Tocris Bioscience (Bristol, UK): Proglumide (Cat #1478/50), the CCK-A receptor antagonist L364,718 (Cat #2304), and the CCK-B receptor antagonist L365,260 (Cat #2767). Peptides or antagonists were prepared in a stock solution and sterilized with a 0.2 µm filter for in vitro cultures.

Jolly G., Duka T., Shivapurkar N., Chen W., Bansal S., Cheema A, & Smith J.P. (2023). Cholecystokinin Receptor Antagonist Induces Pancreatic Stellate Cell Plasticity Rendering the Tumor Microenvironment Less Oncogenic. Cancers, 15(10), 2811.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!